Skip to main content
. 2025 Jun 30;63(8):e00368-25. doi: 10.1128/jcm.00368-25

TABLE 1.

MIC distributions for Pseudomonas aeruginosa and Pseudomonas species other than P. aeruginosa from 2013 to 2022a

Antimicrobial agent Dilution (µg/mL) Total MIC50 MIC90
0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 >
Tobramycin (PA) 561 2,228 10,987 5,298 1,064 342 223 1,849 22,552 0.5 4
Tobramycin (POPA) 57 217 117* 16 7 3 6 15 438 0.25 1
Pip-tazo (PA) 733 338 1,325 9,844 3,203 2,161 1,355 1,039 2,545 22,543 4 >64
Pip-tazo (POPA) 20 38 38 95 132 98 22 11* 15 469 8 32
Imipenem (PA) 245 683 5,736 8,841 1,581 877 1,717 2,863 22,543 1 >8
Imipenem (POPA) 36 102 177 59 25* 24 18 27 468 0.5 4
Meropenem (PA) 125 262 1,287 2,432 4,716 4,224 2,844 1,572 1,299 1,224 1,242 667 645 22,539 0.5 16
Meropenem (POPA) 57 19 18 19 50 135 100 38 31 467 2 8
Cefepime (PA) 59 145 393 3,573 7,978 3,231 3,419 2,183 1,557 22,538 2 16
Cefepime (POPA) 91 54 151 111 24 12* 25 468 2 8
Ceftazidime (PA) 0 1 3 13 84 386 4,117 9,383 2,963 1,501 1,000 1,283 1,805 22,539 2 32
Ceftazidime (POPA) 48 25 66 155 92 19 11* 21 437 2 8
Aztreonam (PA) 3 10 82 381 446 299 906 7,374 6,250 2,581 4,202 22,534 8 >16
Aztreonam (POPA) 5 11 10 9 14 14 42 120 212 437 16 >16
Ciprofloxacin (PA) 562 2,160 9,026 2,890 2,146 1,256 971 747 2,762 22,520 0.12 >4
Ciprofloxacin (POPA) 76 75 150 78 23* 13 5 12 36 468 0.12 4
Levofloxacin (PA) 131 193 437 2,363 9,328 2,591 2,080 1,482 3,910 22,515 0.5 >4
Levofloxacin (POPA) 100 51 143 100 20 10* 43 467 0.5 4
Amikacin (PA) 113 443 742 4,821 9,977 3,690 1,149 501 22,549 4 16
Amikacin (POPA) 27 98 157 110 24* 9 3 0 10 438 1 4
SXT (PA) 808 618 3,481 7,851 9,781 22,539 4 >4
SXT (POPA) 87 35 56 72 218 468 4 >4
a

Pip-tazo: piperacillin-tazobactam; SXT: trimethoprim-sulfamethoxazole. Modal MIC is bolded, and epidemiological cutoff values (ECVs) are indicated by asterisks (*). PA, Pseudomonas aeruginosa; POPA, Pseudomonas species other than P. aeruginosa.